ArticleBMC bioinformatics2025
HLN-DDI: hierarchical molecular representation learning with co-attention mechanism for drug-drug interaction prediction.
Article in BMC bioinformatics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Computational approaches for drug-drug interaction prediction: a systematic review of data sources, modeling strategies, and evaluation frameworks.Frontiers in pharmacology · 2026Pooled it
- Graph-Based Machine Learning for Predicting Drug-Drug Interactions: A Systematic Review.Pharmaceuticals (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundAccurate identification of drug-drug interactions (DDIs) is critical in pharmacology, as DDIs can either enhance therapeutic efficacy or trigger adverse reactions when multiple medications are administered concurrently. Traditional methods for identifying DDIs are labor-intensive and time-consuming, prompting the development of computational alternatives. However, existing computational approaches frequently encounter challenges related to interpretability and struggle to effectively capture the complex, multi-level structures inherent in drug molecules. Specifically, they often fail to adequately analyze substructural components and neglect interactions across hierarchical structural levels, resulting in incomplete molecular representations.
resultsIn this study, we propose a Hierarchical Learning Network with a co-attention mechanism tailored to molecular structure representation for predicting DDIs, named HLN-DDI. The proposed method advances existing approaches by explicitly encoding motif-level structures and capturing hierarchical molecular representations at atom-level, motif-level, and whole-molecule scales. These hierarchical representations are integrated using a co-attention mechanism and combined with interaction-type information to enhance predictive performance. Comprehensive evaluations demonstrate that HLN-DDI significantly outperforms state-of-the-art methods across multiple benchmark datasets, achieving over 98% accuracy under transductive scenarios and surpassing 99% on various evaluation metrics. Moreover, HLN-DDI achieves a notable accuracy improvement of 2.75% in predicting DDIs involving unseen drugs. Practical assessments with real-world DDI scenarios further validate the efficacy and utility of our proposed model.
conclusionBy leveraging hierarchical molecular structures and employing a co-attention mechanism to effectively integrate multi-level representations, HLN-DDI generates comprehensive and precise drug representations, leading to substantially improved predictions of potential drug-drug interactions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.